ivabradine

This page shows the latest ivabradine news and features for those working in and with pharma, biotech and healthcare.

Amgen takes aim at cardio diseases with Arrowhead RNAi deal

Amgen is a recent entrant into the cardiovascular drugs arena, with recently-approved cholesterol-lowering drug Repatha (evolocumab) and heart failure drug Corlaner (ivabradine) spearheading its assault on the market.

Latest news

Amgen agrees to take Cytokinetics' heart failure drug into phase III

It sits among a new generation of heart failure therapies - spearheaded by Novartis' Entresto (sacubitril/valsartan) and Amgen/Servier's Corlanor (ivabradine) - which are trying to advance the treatment of heart
Shire and Baxalta drugs among CHMP's latest recommendations

ANPHARM Przedsiębiorstwo Farmaceutyczne's Ivabradine Anpharm (ivabradine) for the treatment of stable chronic angina pectoris and chronic heart failure.
Amgen starts shipping Corlaner in US

Corlaner (ivabradine) - the first new medicine for chronic heart failure in the US in almost a decade - will be available in pharmacies before the end of the week, according to
FDA clears Amgen's Corlaner for heart failure

The FDA approved Corlaner (ivabradine) after a priority review for reducing the risk of hospitalisation for worsening heart failure in patients with stable, symptomatic chronic heart failure (CHF). ... on ivabradine sales on the back of US approval and a
Amgen banking on three launches in 2015

year. These are evolocumab for high cholesterol, heart failure drug Corlaner (ivabradine) and talimogene laherparepvec (T-VEC) for melanoma.

More from news
Approximately 6 fully matching, plus 7 partially matching documents found.

Latest Intelligence

Heart failure therapy embarks on a new era

While Entresto has captured the headlines of late, there was another key development in HF therapy this year after Amgen secured approval in the US for Corlaner (ivabradine), a drug that ... Ivabradine is thought to be the first drug to work by
Deal Watch table for July 2013

100. ‡‡ Servier / Amgen . Cardiovascular collaboration, licence and option. Procoralan (ivabradine, approved), S38844 (p2), omecamtiv mecarbil (p2). ... Over 40 European countries, Australia, New Zealand . ‡ North America. ‡‡ Amgen receives
Pharma deals during July 2013

Under this agreement, Servier has granted Amgen US rights to Procoralan (ivabradine), which is approved in Europe for chronic heart failure and stable angina in patients with elevated heart rates.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Client Services Director – Healthcare Advertising - London: Neg

Business Unit Head, Medical Communications, London: Excellent package

Client Services Director - Med Comms: Great salary and bebefits

Home based, Senior Medical Writer, Medical Communications: Excellent package

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Editorial Director – Medical Education (MedComms): Neg

Delivery Manager/ Head of Delivery – Executive Search: Neg

Account Manager: £40, 000 - £45, 000 benefits

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Senior Project Manager - Medical Writing: Great salary and bebefits

Home based, Principal Medical Writer, Medical Communications: Excellent package

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Home based, Editorial Team Leader, Medical Communications: Excellent package

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Senior Account Manager: Competitive salary commensurate with experience

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Multi-Channel Account Managers - Road / Homebased – Full or Part...: Competitive salary

Home based, Chief Medical Writer, Medical Communications: Excellent package

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Subscribe to our email news alerts

PMHub

Add my company

PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape: Is it a solution to addressing the challenges of the value-based marketplace?...
Creativity has lost its worth: Creativity has lost its worth, and sadly it is undermining effectiveness...